Sanofi Company Profile (NYSE:SNY)

About Sanofi (NYSE:SNY)

Sanofi logoSanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NYSE:SNY
  • CUSIP: N/A
  • Web: www.sanofi.com
Capitalization:
  • Market Cap: $120.27347 billion
  • Outstanding Shares: 2,525,475,000
Average Prices:
  • 50 Day Moving Avg: $48.25
  • 200 Day Moving Avg: $45.52
  • 52 Week Range: $36.81 - $50.24
P/E:
  • Trailing P/E Ratio: 11.59
  • Foreward P/E Ratio: 14.31
  • P/E Growth: 1.53
Sales & Book Value:
  • Annual Revenue: $40.94 billion
  • Price / Sales: 2.97
  • Book Value: $25.96 per share
  • Price / Book: 1.85
Dividend:
  • Annual Dividend: $1.10
  • Dividend Yield: 2.3%
Profitability:
  • EBIDTA: $12.09 billion
  • Net Margins: 26.55%
  • Return on Equity: 25.89%
  • Return on Assets: 14.24%
Debt:
  • Debt-to-Equity Ratio: 0.29%
  • Current Ratio: 1.62%
  • Quick Ratio: 1.20%
Misc:
  • Average Volume: 1.89 million shs.
  • Beta: 0.89
  • Short Ratio: 1.35
 
Frequently Asked Questions for Sanofi (NYSE:SNY)

What is Sanofi's stock symbol?

Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."

How often does Sanofi pay dividends? What is the dividend yield for Sanofi?

Sanofi announced an annual dividend on Friday, February 17th. Investors of record on Monday, May 15th will be paid a dividend of $1.5771 per share on Wednesday, June 7th. This represents a yield of 3.65%. The ex-dividend date of this dividend is Thursday, May 11th. This is a positive change from Sanofi's previous annual dividend of $1.10. View Sanofi's Dividend History.

How were Sanofi's earnings last quarter?

Sanofi (NYSE:SNY) posted its quarterly earnings data on Friday, April, 28th. The company reported $0.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.73 by $0.03. The business earned $8.65 billion during the quarter, compared to analysts' expectations of $8.40 billion. Sanofi had a net margin of 26.55% and a return on equity of 25.89%. The firm's quarterly revenue was up 1.2% on a year-over-year basis. View Sanofi's Earnings History.

Where is Sanofi's stock going? Where will Sanofi's stock price be in 2017?

13 brokers have issued 1 year price targets for Sanofi's stock. Their predictions range from $55.00 to $93.00. On average, they expect Sanofi's share price to reach $74.00 in the next twelve months. View Analyst Ratings for Sanofi.

Who are some of Sanofi's key competitors?

Who are Sanofi's key executives?

Sanofi's management team includes the folowing people:

  • Serge Weinberg, Independent Chairman of the Board
  • Olivier Brandicourt, Chairman of the Executive Committee, Chief Executive Officer, Director
  • Jerome Contamine, Executive Vice President, Chief Financial Officer, Member of the Executive Committee and the Senior Leadership Team
  • Karen Marie Linehan, Executive Vice President, Legal Affairs and General Counsel, Member of the Executive Committee and the Senior Leadership Team
  • Olivier Charmeil, Executive Vice President and General Manager, General Medicines & Emerging Markets, Member of the Executive Committee and the Senior Leadership Team
  • Peter Guenter, Executive Vice President and General Manager, Diabetes & Cardiovascular, Member of the Executive Committee and the Senior Leadership Team
  • Carsten Hellmann, Executive Vice President and General Manager of Merial, Member of the Executive Committee and the Senior Leadership Team
  • David Loew, Executive Vice President and General Manager of Sanofi Pasteur, Member of the Executive Committee and the Senior Leadership Team
  • David P. Meeker M.D., Executive Vice President and General Manager of Sanofi Genzyme, Member of the Executive Committee and the Senior Leadership Team
  • Roberto Pucci, Executive Vice President, Human Resources, Member of the Executive Committee and the Senior Leadership Team

Who owns Sanofi stock?

Sanofi's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.54%), Aperio Group LLC (0.03%), Russell Investments Group Ltd. (0.02%), Foundation Resource Management Inc. (0.01%), Bank of Montreal Can (0.01%) and Manning & Napier Advisors LLC (0.01%). View Institutional Ownership Trends for Sanofi.

Who sold Sanofi stock? Who is selling Sanofi stock?

Sanofi's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Douglas Lane & Associates LLC, Jarislowsky Fraser Ltd, Country Club Trust Company n.a., Cribstone Capital Management LLC, Capstone Asset Management Co., Fulton Bank N.A. and CENTRAL TRUST Co. View Insider Buying and Selling for Sanofi.

Who bought Sanofi stock? Who is buying Sanofi stock?

Sanofi's stock was purchased by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Aperio Group LLC, Russell Investments Group Ltd., Capital Asset Advisory Services LLC, Boston Advisors LLC, Gradient Investments LLC, Cullinan Associates Inc. and Visionary Asset Management Inc.. View Insider Buying and Selling for Sanofi.

How do I buy Sanofi stock?

Shares of Sanofi can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sanofi's stock price today?

One share of Sanofi stock can currently be purchased for approximately $48.07.


MarketBeat Community Rating for Sanofi (NYSE SNY)
Community Ranking:  2.2 out of 5 ( )
Outperform Votes:  202 (Vote Outperform)
Underperform Votes:  258 (Vote Underperform)
Total Votes:  460
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sanofi (NYSE:SNY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 7 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.15)
Consensus Price Target: $74.00 (53.94% upside)

Analysts' Ratings History for Sanofi (NYSE:SNY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/9/2017ArgusBoost Price TargetBuy$50.00 -> $55.00LowView Rating Details
5/11/2017Berenberg BankDowngradeBuy -> HoldLowView Rating Details
4/20/2017J P Morgan Chase & CoReiterated RatingNeutralMediumView Rating Details
4/7/2017HSBC Holdings plcDowngradeHold -> ReduceLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageHold -> HoldLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageUnderweightN/AView Rating Details
2/9/2017NatixisUpgradeNeutral -> BuyN/AView Rating Details
1/10/2017Leerink SwannReiterated RatingOutperformN/AView Rating Details
1/8/2017Goldman Sachs Group, Inc. (The)Reiterated RatingHoldN/AView Rating Details
11/29/2016Morgan StanleyUpgradeEqual Weight -> OverweightN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageNeutralN/AView Rating Details
9/14/2016Jefferies Group LLCReiterated RatingHoldN/AView Rating Details
9/13/2016BNP ParibasUpgradeUnderperform -> NeutralN/AView Rating Details
6/28/2016Citigroup Inc.Reiterated RatingNeutralN/AView Rating Details
5/3/2016Bank of America CorporationReiterated RatingBuy$58.00N/AView Rating Details
4/12/2016Chardan CapitalReiterated RatingBuyN/AView Rating Details
2/10/2016Sanford C. BernsteinLower Price TargetMarket-Perform$52.00 -> $45.00N/AView Rating Details
12/16/2015Oddo SecuritiesDowngradeReduceN/AView Rating Details
11/9/2015Bryan, Garnier & CoReiterated RatingBuy -> NeutralN/AView Rating Details
9/16/2015Sarasin & PartnersUpgradeBuyN/AView Rating Details
(Data available from 7/26/2015 forward)

Earnings

Earnings History for Sanofi (NYSE:SNY)
Earnings by Quarter for Sanofi (NYSE:SNY)
Earnings History by Quarter for Sanofi (NYSE SNY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/28/20173/31/2017$0.73$0.76$8.40 billion$8.65 billionViewN/AView Earnings Details
2/8/2017Q416$0.66$0.67$9.87 billion$8.88 billionViewN/AView Earnings Details
10/29/2015Q315$0.88$0.89$10.97 billion$10.67 billionViewN/AView Earnings Details
4/30/2015Q115$0.61$0.73$9.21 billion$9.78 billionViewN/AView Earnings Details
2/5/2015Q4$0.89$0.79$11.34 billion$10.39 billionViewN/AView Earnings Details
7/31/2014Q2$0.79$0.72$11.19 billion$10.82 billionViewN/AView Earnings Details
4/29/2014Q114$0.84$0.81$11.19 billion$10.88 billionViewN/AView Earnings Details
2/6/2014Q4$0.88$0.93ViewN/AView Earnings Details
10/30/2013$1.01$0.93ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sanofi (NYSE:SNY)
2017 EPS Consensus Estimate: $3.21
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.75$0.78$0.77
Q2 20171$0.74$0.74$0.74
Q3 20171$0.90$0.90$0.90
Q4 20171$0.80$0.80$0.80
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Sanofi (NYSE:SNY)
Most Recent Dividend:6/7/2017
Annual Dividend:$1.10
Dividend Yield:2.29%
Dividend Growth:-2.50% (3 Year Average)
Payout Ratio:27.64% (Trailing 12 Months of Earnings)
34.38% (Based on This Year's Estimates)
32.74% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Sanofi (NYSE:SNY)

Dividend History by Quarter for Sanofi (NYSE SNY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/17/2017annual$1.583.65%5/11/20175/15/20176/7/2017
2/22/2016Annual$1.105/5/20165/9/20166/1/2016
2/26/2015special$1.623.91%5/6/20155/8/20156/2/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Sanofi (NYSE:SNY)
Insider Ownership Percentage: 1.00%
Institutional Ownership Percentage: 9.97%
Insider Trades by Quarter for Sanofi (NYSE:SNY)
Institutional Ownership by Quarter for Sanofi (NYSE:SNY)
Insider Trades by Quarter for Sanofi (NYSE:SNY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/9/2014SanofiMajor ShareholderBuy195,000$308.27$60,112,650.00View SEC Filing  
7/8/2014SanofiMajor ShareholderBuy153,000$311.67$47,685,510.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Sanofi (NYSE:SNY)
Latest Headlines for Sanofi (NYSE:SNY)
Source:
DateHeadline
americanbankingnews.com logo Brokerages Anticipate Sanofi (NYSE:SNY) Will Announce Quarterly Sales of $9.98 Billion
www.americanbankingnews.com - July 23 at 11:52 AM
streetinsider.com logoSanofi (SNY) and Regeneron (REGN) Receive Positive CHMP Opinion for Dupixent to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
www.streetinsider.com - July 23 at 8:15 AM
finance.yahoo.com logoRegeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
finance.yahoo.com - July 23 at 8:15 AM
finance.yahoo.com logoSanofi Receives CHMP Positive Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
finance.yahoo.com - July 23 at 8:15 AM
nasdaq.com logoMerck's Biosimilar Insulin Gets Tentative FDA Approval - Nasdaq
www.nasdaq.com - July 22 at 8:59 AM
nasdaq.com logoMerck's Biosimilar Insulin Gets Tentative FDA Approval - Nasdaq
www.nasdaq.com - July 22 at 8:59 AM
streetinsider.com logoSanofi (SNY) and Regeneron (REGN) Receive Positive CHMP ... - StreetInsider.com
www.streetinsider.com - July 22 at 8:59 AM
streetinsider.com logoSanofi (SNY) and Regeneron (REGN) Receive Positive CHMP ... - StreetInsider.com
www.streetinsider.com - July 22 at 8:59 AM
americanbankingnews.com logoSanofi (SNY) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 21 at 10:40 PM
americanbankingnews.com logoSanofi (SNY) Expected to Announce Earnings of $0.75 Per Share
www.americanbankingnews.com - July 21 at 8:08 AM
nasdaq.com logoFDA tentatively approves Merck's copycat of Sanofi's Lantus - Nasdaq
www.nasdaq.com - July 21 at 7:16 AM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE- Sears, Nike, Sarepta ... - Nasdaq - Nasdaq
www.nasdaq.com - July 21 at 7:16 AM
seekingalpha.com logoAblynx and Sanofi team up to develop Nanobody-based therapeutics for inflammatory diseases; Sanofi up 2% premarket - Seeking Alpha
seekingalpha.com - July 20 at 7:55 AM
streetinsider.com logoSanofi Pasteur (SNY) Ships First Influenza Vaccine Doses for 2017-2018 Season
www.streetinsider.com - July 19 at 1:49 AM
finance.yahoo.com logoSanofi Pasteur Ships First of its U.S. Influenza Vaccine Doses for 2017-2018 Season
finance.yahoo.com - July 19 at 1:49 AM
streetinsider.com logoSanofi Pasteur (SNY) Ships First Influenza Vaccine Doses for 2017 ... - StreetInsider.com
www.streetinsider.com - July 18 at 8:22 AM
seekingalpha.com logoEmergent BioSolutions buys smallpox vaccine assets from Sanofi unit for up to $125M
seekingalpha.com - July 15 at 8:50 AM
finance.yahoo.com logoPfizer Xeljanz Label Expansion Application Accepted by FDA
finance.yahoo.com - July 15 at 8:50 AM
americanbankingnews.com logoSanofi Sees Unusually High Options Volume (SNY)
www.americanbankingnews.com - July 15 at 7:16 AM
streetinsider.com logoEmergent BioSolutions (EBS) to Acquire ACAM2000 Business From Sanofi (SNY) for $125M - StreetInsider.com
www.streetinsider.com - July 14 at 8:32 AM
finance.yahoo.com logoPharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co.
finance.yahoo.com - July 14 at 8:32 AM
finanznachrichten.de logoPro-Trader Daily: Featured Company News - Sanofi to Buy Vaccines Biotech Company Protein Sciences
www.finanznachrichten.de - July 13 at 9:44 AM
streetinsider.com logoSanofi (SNY) Releases Pre-quarterly Q2 Results
www.streetinsider.com - July 13 at 9:44 AM
finance.yahoo.com logoFeatured Company News - Sanofi to Buy Vaccines Biotech Company Protein Sciences
finance.yahoo.com - July 13 at 9:44 AM
seekingalpha.com logoSanofi Switches Eggs For Insects With Vaccines Move
seekingalpha.com - July 12 at 1:29 AM
finance.yahoo.com logoSanofi Steps Up M&A Activity With $650 Million Purchase of Protein Sciences
finance.yahoo.com - July 12 at 1:29 AM
cnbc.com logoWall Street under pressure ahead of key Fed speeches this week - CNBC
www.cnbc.com - July 11 at 3:27 PM
streetinsider.com logoAlnylam Pharma (ALNY) & Sanofi (SNY) Genzyme Announce ... - StreetInsider.com
www.streetinsider.com - July 11 at 7:54 AM
streetinsider.com logoSanofi (SNY) to Acquire Protein Sciences for $650M Plus Milestones - StreetInsider.com
www.streetinsider.com - July 11 at 7:54 AM
seekingalpha.com logoSanofi to buy Protein Sciences
seekingalpha.com - July 11 at 5:01 AM
feeds.benzinga.com logoSanofi Genzyme and Alnylam Report Positive Results from Ongoing phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or...
feeds.benzinga.com - July 10 at 10:16 AM
finance.yahoo.com logoEndo (ENDP) to Remove Opioid Pain Drug Opana ER from Market
finance.yahoo.com - July 8 at 9:14 AM
streetinsider.com logoAlnylam Pharma (ALNY), Sanofi (SNY) Initiate Phase 3 Program for Fitusiran for Hemophilia A and B
www.streetinsider.com - July 7 at 12:37 PM
americanbankingnews.com logoSanofi SA (NYSE:SNY) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - July 5 at 5:02 PM
prnewswire.com logoBreakfast Technical Briefing on Drug Makers Stocks -- Bristol Myers Squibb ...
www.prnewswire.com - July 5 at 10:52 AM
nasdaq.com logoWhy Sanofi is a Top 10 SAFE International Dividend Stock
www.nasdaq.com - July 5 at 10:52 AM
finance.yahoo.com logo'Despicable Me 3' Tops Weekend Box Office
finance.yahoo.com - July 5 at 10:52 AM
nasdaq.com logoHealth Care Sector Update for 06/30/2017: REGN,SNY,SKLN,CARA - Nasdaq
www.nasdaq.com - July 1 at 7:41 AM
streetinsider.com logoAlnylam (ALNY) Sanofi (SNY) Genzyme to Present New Clinical ... - StreetInsider.com
www.streetinsider.com - June 28 at 1:01 AM
streetinsider.com logoSanofi (SNY) & Regeneron (REGN) Granted EU Marketing Approval from Kevzara (sarilumab) in Combination with ... - StreetInsider.com
www.streetinsider.com - June 28 at 1:01 AM
bizjournals.com logoAmerican Academy of Family Physicians Foundation Launches Highlight on VACCINATIONS 4 TEENS to Help Address Teen Under-Vaccination
www.bizjournals.com - June 27 at 8:00 PM
zacks.com logoSanofi/Regeneron's Kevzara Gets Marketing Approval in EU
www.zacks.com - June 27 at 8:00 PM
seekingalpha.com logoRegeneron and Sanofi's Kevzara OK'd in Europe for rheumatoid arthritis
seekingalpha.com - June 27 at 8:29 AM
streetinsider.com logoAlnylam (ALNY) Sanofi (SNY) Genzyme to Present New Clinical Trial Results at ISTH
www.streetinsider.com - June 27 at 8:29 AM
finance.yahoo.com logo[$$] Third Point Move Could Lead to Nestlé-L’Oréal Decoupling
finance.yahoo.com - June 27 at 8:29 AM
americanbankingnews.com logoSanofi (SNY) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - June 26 at 10:02 PM
americanbankingnews.com logoSanofi (SNY) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - June 23 at 5:54 PM
finance.yahoo.com logoDrugmakers May Lose $390B In Sales Over 5 Years
finance.yahoo.com - June 22 at 6:42 PM
nasdaq.com logoSanofi: Should Value Investors Consider SNY Stock? - Nasdaq
www.nasdaq.com - June 21 at 5:40 AM
finance.yahoo.com logoSanofi: Should Value Investors Consider SNY Stock?
finance.yahoo.com - June 20 at 8:02 AM

Social

Chart

Sanofi (SNY) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff